Dr Peter Hillmen speaks with ecancertv at BSH 2016, reviewing the results from the RESONATE2 trial of ibrutinib and CLL115 trial of idelalisib.

These results are also reviewed by Dr George Follows and Dr Andrew Zelenetz, though Dr Hillmen draws specific attention to toxicity profile exhibited by some idelalisib patients with a history of autoimmune disease.

Looking forward, he describes the ongoing goals of reducing toxicity, isolating resistance and the risk-reward balance of combination therapies.

ecancer's filming at ICMM 2016 has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.